CogState releases details of UBC agreement

By Dylan Bushell-Embling
Tuesday, 29 July, 2008

Melbourne's CogState [ASX: CGS] has released the terms of its planned partnership with US pharmaceutical services company United BioSource Corporation [UBC], announced last week.

Under the arrangement, CogState and UBC will join forces to provide a comprehensive cognitive testing solution for use in clinical trials.

CogState markets six computerised diagnostic products to test cognitive function. It also has a therapeutic division with two compounds in early develop for Alzheimer's and Parkinson's diseases.

Under the agreement, UBC will buy a 15 per cent share in CogState, at a cost of around $800,000. UBC will also underwrite CogState's share rights issue.

Both companies will remain separate entities. In a statement to the stock exchange, CogState stressed that the arrangement will not necessitate any management changes or job losses.

Related News

Exclusive colostrum intake may reduce risk of food allergies

Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...

Sunscreen and supplements can lower your vitamin D levels

People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...

Low-dose drug prevents diabetes progression in young people

A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd